What is AOD-9604?
AOD-9604 is a peptide based on a fragment of the human growth hormone molecule, promoted for fat loss. The WADA Prohibited List classes it under growth hormone fragments, alongside hGH 176-191, and bans it for tested athletes at all times.
It has never reached FDA approval as a drug. That is the root of the availability problem: with no approved product, the only legal route to patients would be pharmacy compounding, and that route is closed.
Why can’t pharmacies compound it?
Because it does not meet the conditions. Under the FDA’s 503A rules, a pharmacy may only compound from a bulk substance that has a USP or NF monograph, is a component of an FDA-approved drug, or is on the FDA’s 503A bulks list. AOD-9604 has none of the three.
It was nominated for the bulks list, then placed in the FDA’s Category 2 for substances that may present significant safety risks, and the nomination was later withdrawn. The FDA’s Category 2 page records its concerns:
- possible immunogenicity, meaning an immune reaction, by some routes of administration
- difficulty characterizing the ingredient and its impurities
- little or no safety information, so the agency could not judge whether it harms people
- serious adverse events that may be associated with it, though causality is unclear
A withdrawn nomination does not make it eligible. It means the question is simply no longer in front of the FDA.
What does Ultimate Male offer for belly fat instead?
Two options with real human data behind them. Which one fits depends on whether your problem is mainly deep belly fat or overall weight.
| AOD-9604 | Tesamorelin | Semaglutide or tirzepatide | |
|---|---|---|---|
| FDA status | Not approved | Approved (Egrifta) for HIV-associated abdominal fat; off-label otherwise | Approved for weight management |
| Source | Unregulated sellers only | The FDA-approved product; not compounded | Through a medical weight loss plan |
| Main target | Claimed fat loss | Visceral fat around the organs | Overall body weight |
| Human trial data | Not established | Phase 3 trials in HIV; a 12-month trial in obese adults without HIV | Large weight loss trials |
Tesamorelin’s label on DailyMed covers excess abdominal fat in adults with HIV. In a 12-month trial in abdominally obese adults without HIV, visceral fat fell on tesamorelin while it rose on placebo, fat under the skin did not change significantly, and triglycerides improved. Our tesamorelin page covers dosing, monitoring and side effects.
Which option fits which man?
Tesamorelin suits a specific pattern: a firm, protruding belly in a man who is not especially heavy elsewhere, often with high triglycerides. A medical weight loss plan with semaglutide or tirzepatide suits men who have more weight to lose overall. Our comparison of tesamorelin vs GLP-1 medicines for visceral fat sets them side by side.
Measurement helps decide. A body composition analysis shows how much of your weight is fat and where it sits, which a bathroom scale cannot.
Related question: do any peptides help weight loss?
Some do, and some are mostly marketing. Our page on which peptides help weight loss separates the ones with trial data from the ones without, and our page on visceral fat in men explains why belly fat is a health issue, not just a cosmetic one.
Building a fat-loss plan at Ultimate Male
Start with the free 10-minute call, then labs at our San Gabriel or Downey clinic. Fasting glucose, A1C, lipids, testosterone and IGF-1 all affect which option is safe and which is likely to work.
At the consultation, the provider explains each option’s FDA status in plain terms, including that tesamorelin is off-label for men without HIV. You leave knowing what is realistic, what monitoring looks like, and which plan fits your body rather than a trend.
